Mirum Pharmaceuticals, Inc. (MIRM:NASDAQ) closed at $93.99 on November 13, 2026, up 0.71% on the day. The stock trades 27.7% below its 52-week high of $130.00 and 48.6% above its 52-week low of $63.23. Over the past year, it gained 31.6%. Mirum Pharmaceuticals, Inc. is part of the Health Care sector (Major Pharmaceuticals).
In 252 trading sessions since November 13, 2025, MIRM closed higher on 143 days (57%). Its best day was November 4, 2026 (+11.42%) and its worst was February 26, 2026 (-15.13%). The stock moved 10% or more in a single session 4 times.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of therapies for debilitating liver diseases. It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
Find more stocks like MIRM with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.